Analyst firms · BofA Securities · MRNA

BofA Securities MRNA price target and rating history

Moderna Inc. (MRNA) · Health Care

BofA Securities rates Moderna Inc. (MRNA) Neutral with a $41 price target, as of its latest action on Aug 19, 2026. It has published 3 rating actions on MRNA since January 2022, including 2 upgrades and 0 downgrades. Across 6 firms with a MRNA price target in the last 12 months, the median target is $57.

Current rating
Neutral
Price target
$41
Median target, all firms
$57
Actions on MRNA
3

BofA Securities price target on MRNA

$180$111$412023202420252026
BofA Securities price target on MRNA, each point a stated target, January 2022 to December 2024.

Every BofA Securities rating on MRNA

How other firms rate MRNA

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
William BlairMkt PerformOct 27, 2026
CitigroupSell$80Sep 30, 2026
Rothschild & Co RedburnSell$81Sep 3, 2026
Argus ResearchBuy$180Aug 28, 2026
Wolfe ResearchPeer PerformAug 25, 2026
BofA SecuritiesNeutralAug 19, 2026
BarclaysEqual Weight$25Jan 28, 2026
UBSNeutral$34Jan 7, 2026
JefferiesHold$30Dec 12, 2025

Questions about BofA Securities and MRNA

What is BofA Securities's price target for MRNA?
BofA Securities's latest stated price target for Moderna Inc. (MRNA) is $41, from its action on Dec 10, 2024.
What is BofA Securities's rating on MRNA?
BofA Securities rates MRNA Neutral, a neutral rating, as of Aug 19, 2026.
When did BofA Securities last change its view on MRNA?
On Aug 19, 2026, BofA Securities upgrades to Neutral from Underperform.
How does BofA Securities's MRNA target compare with other analysts?
Across 6 firms with a MRNA price target in the last 12 months, the median target is $57.

More MRNA rating histories

All BofA Securities ratingsMRNA news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.